CODA
MCID: CVT001
MIFTS: 38

Cavitary Optic Disc Anomalies (CODA)

Categories: Eye diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Cavitary Optic Disc Anomalies

MalaCards integrated aliases for Cavitary Optic Disc Anomalies:

Name: Cavitary Optic Disc Anomalies 56 73 36 29 13 6 71
Coda 56 73
Familial Cavitary Optic Disc Anomaly 58
Eye Diseases, Hereditary 43
Familial Coda 58

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
onset of symptoms in adolescence or early adulthood
broad spectrum of optic nerve head anomalies, with significant inter-eye differences in some patients
more than half of patients develop retinal detachments and/or retinoschisis later in life
some patients are asymptomatic and diagnosed incidentally


HPO:

31
cavitary optic disc anomalies:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare eye diseases
Developmental anomalies during embryogenesis


External Ids:

OMIM 56 611543
KEGG 36 H02270
MeSH 43 D015785
Orphanet 58 ORPHA464760
MedGen 41 C1969063
UMLS 71 C1969063

Summaries for Cavitary Optic Disc Anomalies

UniProtKB/Swiss-Prot : 73 Cavitary optic disc anomalies: An ocular disease characterized by a profound excavation of the optic nerve. Clinical phenotype is variable and includes congenitally excavated optic nerves as well as other features of optic pit, optic nerve coloboma, and morning glory disk anomaly. Patients with CODA have a strong predilection for retinal detachment and/or separation of the retinal layers (retinoschisis) that lead to profound central vision loss.

MalaCards based summary : Cavitary Optic Disc Anomalies, also known as coda, is related to codas syndrome and even-plus syndrome. An important gene associated with Cavitary Optic Disc Anomalies is MMP19 (Matrix Metallopeptidase 19). The drugs Cysteine and Central Nervous System Depressants have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and liver, and related phenotypes are nyctalopia and peripapillary atrophy

KEGG : 36 Congenital cavitary optic disc anomalies (CODA) include optic disc coloboma, morning glory disc anomaly, optic pit, and the papillorenal syndrome. Recently, a copy number variation upstream of matrix metalloproteinase 19 (MMP19) has been discovered in an autosomal dominant pedigree with CODA.

More information from OMIM: 611543

Related Diseases for Cavitary Optic Disc Anomalies

Graphical network of the top 20 diseases related to Cavitary Optic Disc Anomalies:



Diseases related to Cavitary Optic Disc Anomalies

Symptoms & Phenotypes for Cavitary Optic Disc Anomalies

Human phenotypes related to Cavitary Optic Disc Anomalies:

31
# Description HPO Frequency HPO Source Accession
1 nyctalopia 31 occasional (7.5%) HP:0000662
2 peripapillary atrophy 31 very rare (1%) HP:0500087
3 visual field defect 31 HP:0001123
4 reduced visual acuity 31 HP:0007663

Symptoms via clinical synopsis from OMIM:

56
Head And Neck Eyes:
decreased visual acuity
visual field defects
night blindness (rare)
colobomatous optic nerve head (in some patients)
optic nerve head pit (in some patients)
more

Clinical features from OMIM:

611543

Drugs & Therapeutics for Cavitary Optic Disc Anomalies

Drugs for Cavitary Optic Disc Anomalies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cysteine Approved, Nutraceutical Phase 2, Phase 3 52-90-4 5862
2 Central Nervous System Depressants Phase 3
3 Anesthetics Phase 3
4 Pharmaceutical Solutions Phase 3
5 Anti-Infective Agents, Local Phase 3
6
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
7
Doxycycline Approved, Investigational, Vet_approved Phase 1, Phase 2 564-25-0 54671203
8
Oxytetracycline Approved, Investigational, Vet_approved Phase 1, Phase 2 79-57-2 5280972 54715139
9
Hydromorphone Approved, Illicit Phase 2 466-99-9 5284570
10
Pirfenidone Approved, Investigational Phase 2 53179-13-8 40632
11 Neurotransmitter Agents Phase 2
12 Tranquilizing Agents Phase 2
13 GABA Agents Phase 2
14 Anticonvulsants Phase 2
15 Antimanic Agents Phase 2
16 Psychotropic Drugs Phase 2
17 Antimalarials Phase 1, Phase 2
18 Narcotics Phase 2
19 Analgesics, Opioid Phase 2
20 Anti-Inflammatory Agents Phase 2
21 Antirheumatic Agents Phase 2
22 Analgesics Phase 2
23 Liver Extracts Phase 2
24 Anti-Inflammatory Agents, Non-Steroidal Phase 2
25 Analgesics, Non-Narcotic Phase 2
26
Cefotaxime Approved 63527-52-6 456256 5742673
27
Ciprofloxacin Approved, Investigational 85721-33-1 2764
28
Ceftriaxone Approved 73384-59-5 5479530 5361919
29
Cefazolin Approved 25953-19-9 656510 33255
30
Cefuroxime Approved 55268-75-2 5361202 5479529
31
Ticarcillin Approved, Investigational, Vet_approved 34787-01-4 36921
32
Tigecycline Approved 220620-09-7 5282044
33
Levofloxacin Approved, Investigational 100986-85-4 149096
34
Norgestimate Approved, Investigational 35189-28-7 6540478
35
Cefoxitin Approved 35607-66-0 441199
36
Clavulanate Approved, Vet_approved 58001-44-8 5280980
37
Metronidazole Approved 443-48-1 4173
38
Ofloxacin Approved 82419-36-1 4583
39
Moxifloxacin Approved, Investigational 151096-09-2, 354812-41-2 152946
40
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
41
Clindamycin Approved, Vet_approved 18323-44-9 29029
42
Polyestradiol phosphate Approved 28014-46-2
43
Ertapenem Approved, Investigational 153832-46-3 150610
44
Ethinyl Estradiol Approved 57-63-6 5991
45 (T,G)-A-L
46 Adjuvants, Immunologic
47 Immunosuppressive Agents
48 Immunologic Factors
49
Glatiramer Acetate 147245-92-9 3081884
50 Lemon Balm

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Targeted Hip Progressive Resistance Training to Improve Single Leg Balance and Walking in Children With Cerebral Palsy Unknown status NCT01633736 Phase 3
2 Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene Completed NCT02652780 Phase 3
3 Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene Recruiting NCT03913143 Phase 2, Phase 3 QR-110
4 Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year Active, not recruiting NCT03293524 Phase 3 Placebo
5 A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene Active, not recruiting NCT02652767 Phase 3
6 The Effect of Subantimicrobial Dose Doxycycline in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
7 Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa Completed NCT01399515 Phase 2 Valproic Acid
8 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study Completed NCT01727973 Phase 1, Phase 2 Doxycycline
9 A Randomized, Double-Blind, Vehicle-controlled, Parallel Group, Dose-Ranging, Multi-center Study of the Efficacy and Safety of Nexagon® in the Treatment of Participants With Venous Leg Ulcers Completed NCT00820196 Phase 2 Nexagon®;Nexagon® vehicle
10 A Randomized, Parallel Group, Dose-Ranging, Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nexagon® in the Treatment of Subjects With a Venous Leg Ulcer Completed NCT01199588 Phase 2 Nexagon® Low Dose;Nexagon® High Dose;Nexagon® Vehicle
11 A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-ranging, Multi-center Study to Assess the Safety and Clinical Effect of Nexagon® in the Treatment of Subjects With a Diabetic Foot Ulcer Completed NCT01490879 Phase 2 Nexagon® Low Dose;Nexagon® Medium Dose;Nexagon® High Dose;Nexagon® vehicle
12 Safety and Speed of Onset of a Fixed Dose of Intravenous Hydromorphone in the Treatment of Adult Patients Presenting to the Emergency Department With Acute Severe Pain Completed NCT00305110 Phase 2 2 mg IV hydromorphone
13 A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa Recruiting NCT03326336 Phase 1, Phase 2
14 Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression Recruiting NCT03328130 Phase 1, Phase 2
15 Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of AGN-151587 (EDIT-101) in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26") Recruiting NCT03872479 Phase 1, Phase 2 AGN-151587
16 A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene Recruiting NCT03780257 Phase 1, Phase 2 QR-421a
17 A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene Recruiting NCT04123626 Phase 1, Phase 2 QR-1123
18 An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene Recruiting NCT03913130 Phase 1, Phase 2 QR-110
19 Pirfenidone in Combination With Standard of Care Treatment in Patients With Advanced Liver Fibrosis. Multicenter, Open Trial Focused on Safety, Fibrosis Efficacy Evaluation, and Pharmacokinetic Data. Recruiting NCT04099407 Phase 2 Pirfenidone
20 A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-escalation, Single-center Study of the Safety and Clinical Effect of Nexagon® in the Treatment of Participants With Diabetic Foot Ulcers Terminated NCT00820703 Phase 1, Phase 2 Nexagon®;Nexagon® vehicle
21 A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon® in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries. Withdrawn NCT00821561 Phase 2 Nexagon®;Nexagon® vehicle
22 A Phase 1 Randomized, Prospective, Double-Masked, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon™ in Subjects Following Bilateral Photorefractive Keratectomy (PRK) for the Correction of Mild to Moderate Myopia. Completed NCT00654550 Phase 1 Nexagon™ or Nexagon™ vehicle
23 Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate Unknown status NCT00331747 Glatiramer acetate
24 Fundus Changes in the Microphthalmy Eyes Completed NCT00811512
25 Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients: A Prospective Multicenter Clinical Study Based on Randomized Intra-individual Implant Activation in Patients With Degenerative Retinal Diseases Completed NCT01024803
26 Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Inherited Ophthalmic Diseases Completed NCT00001732
27 Evaluation and Treatment Protocol for Potential Research Subjects With Inherited Ophthalmic Diseases Completed NCT00011817
28 The Role of the Peroneus Brevis and Peroneus Longus in Patients With Chronic Ankle Instability and the Effect of an Exercise Intervention Completed NCT02276339
29 Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2) Recruiting NCT02946879
30 Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials Recruiting NCT03406104
31 Natural History Study of CEP290-Related Retinal Degeneration Recruiting NCT03396042
32 Observational Registry Study of Leber Hereditary Optic Neuropathy (LHON) Affected Patients Recruiting NCT03295071
33 Foundation Fighting Blindness Registry, My Retina Tracker Recruiting NCT02435940
34 The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial Recruiting NCT02800785 Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin
35 Coordination of Rare Diseases at Sanford Recruiting NCT01793168
36 COMPLICATIONS OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY- AN INDIAN PERSPECTIVE Active, not recruiting NCT04062617
37 EAP Single Patient: Safety of Bilateral Intravitreal Injection of GS010 in a Single Subject Affected With G11778A ND4 Leber Hereditary Optic Neuropathy Available NCT03672968
38 Pilot Study of Intravitreal Bevacizumab vs. Combination Therapy for Choroidal Neovascularization Secondary to Causes Other Than Age-related Macular Degeneration Withdrawn NCT01256580 Bevacizumab (Avastin; Genentech, Inc.);Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy

Search NIH Clinical Center for Cavitary Optic Disc Anomalies

Cochrane evidence based reviews: eye diseases, hereditary

Genetic Tests for Cavitary Optic Disc Anomalies

Genetic tests related to Cavitary Optic Disc Anomalies:

# Genetic test Affiliating Genes
1 Cavitary Optic Disc Anomalies 29 MMP19

Anatomical Context for Cavitary Optic Disc Anomalies

MalaCards organs/tissues related to Cavitary Optic Disc Anomalies:

40
Eye, Testes, Liver, Bone, Retina, Heart, Skin

Publications for Cavitary Optic Disc Anomalies

Articles related to Cavitary Optic Disc Anomalies:

(show top 50) (show all 646)
# Title Authors PMID Year
1
Heterozygous triplication of upstream regulatory sequences leads to dysregulation of matrix metalloproteinase 19 in patients with cavitary optic disc anomaly. 61 56 6
25581579 2015
2
Progressive optic nerve cupping and neural rim decrease in a patient with bilateral autosomal dominant optic nerve colobomas. 56 6
10764862 2000
3
The spectrum of cavitary optic disc anomalies in a family. 61 56
2710526 1989
4
Familial cavitary optic disk anomalies: identification of a novel genetic locus. 56
17368552 2007
5
Familial cavitary optic disk anomalies: clinical features of a large family with examples of progressive optic nerve head cupping. 56
17362864 2007
6
Optic nerve colobomas of autosomal-dominant heredity. 56
945057 1976
7
Overexpression and one-step renaturation-purification of the tagged creatinine deiminase of Corynebacterium glutamicum in Escherichia coli cells. 61
32039507 2020
8
Use of Compositional Data Analysis to Show Estimated Changes in Cardiometabolic Health by Reallocating Time to Light-Intensity Physical Activity in Older Adults. 61
31350674 2020
9
Structure Dependent Determination of Organophosphate Targets in Mammalian Tissues Using Activity-Based Protein Profiling. 61
31872761 2020
10
Toward Noninvasive Mapping of Diffuse Scattering in the Presence of Motion. 61
31937210 2020
11
Enzymes Photo-Cross-Linked to Live Cell Receptors Retain Activity and EGFR Inhibition after Both Internalization and Recycling. 61
31840981 2020
12
The coordination of upper and lower limbs in curve-turning walking of healthy preschoolers: Viewed in continuous relative phase. 61
31586751 2020
13
Cervical Range of Motion after Anterior Corpectomy and Fusion versus Laminoplasty for Multilevel Cervical Spondylotic Myelopathy: A Three-Dimensional Comparison Based on the Coda Motion System. 61
31491573 2019
14
Individual categorisation of glucose profiles using compositional data analysis. 61
30380996 2019
15
Novel stress phonotactics are learnable by English speakers: Novel tone phonotactics are not. 61
31879827 2019
16
Clear versus casual consonant identification by hearing-impaired and normal-hearing listeners. 61
31801385 2019
17
Phonological selectivity in the acquisition of English clusters. 61
31434589 2019
18
Co-occurring defect analysis: A platform for analyzing birth defect co-occurrence in registries. 61
31313535 2019
19
Nonlinear Coda Wave Interferometry: Sensitivity to wave-induced material property changes analyzed via numerical simulations in 2D. 61
31419760 2019
20
Toward the combined optimization of dynamic axes (CODA) for stereotactic radiotherapy and radiosurgery using fixed couch trajectories. 61
31659750 2019
21
Correlation between Physical Activity and Lung Function in Dusty Areas: Results from the Chronic Obstructive Pulmonary Disease in Dusty Areas (CODA) Cohort. 61
31172706 2019
22
Corporate social responsibility and financial profile of Spanish private hospitals. 61
31667425 2019
23
Assessing the effect of season, montanera length and sampling location on Iberian pig fat by compositional data analysis and standard multivariate statistics. 61
31174772 2019
24
Does cardiac rehabilitation for people with stroke in the sub-acute phase of recovery lead to physical behaviour change? Results from compositional analysis of accelerometry-derived data. 61
32026825 2019
25
Two new species of deep-sea sponges (Porifera, Demospongiae) from submarine canyons of the Sardinian continental margin (western Mediterranean Sea). 61
31719441 2019
26
Preclinical Competency Testing in North American Dental Schools and Opinions About Possible Standardization. 61
31658982 2019
27
Early Clinical Exposure in U.S. Dental Schools and Correlation with Earlier Competencies Evaluation. 61
31658983 2019
28
Tracking fluids in multiple scattering and highly porous materials: Toward applications in non-destructive testing and seismic monitoring. 61
31671364 2019
29
Deep Machine Learning Techniques for the Detection and Classification of Sperm Whale Bioacoustics. 61
31467331 2019
30
Relations between socio-economic factors and nutritional diet in Vietnam from 2004 to 2014: New insights using compositional data analysis. 61
29683048 2019
31
Calibration of Self-Reported Time Spent Sitting, Standing and Walking among Office Workers: A Compositional Data Analysis. 61
31461868 2019
32
The occlusion balloon reduction technique for de novo placement and salvage of malpositioned enteric tubes. 61
31065744 2019
33
Patient-Specific, Risk-Based Prevention, Maintenance, and Supportive Care: A Need for Action and Innovation in Education. 61
30924568 2019
34
Narrative Production in Arabic-speaking Adolescents with and without Hearing Loss. 61
30668867 2019
35
Velocity and Power-Load Association of Bench Press Exercise in Wheelchair Basketball Players and Their Relationships With Field-Test Performance. 61
30569792 2019
36
Is there adaptation of speech production after speech perception in bilingual interaction? 61
30265054 2019
37
In Reply to Coda. 61
31241571 2019
38
Monitoring cleaning cycles of fouled ducts using ultrasonic coda wave interferometry (CWI). 61
30745025 2019
39
Write a Scientific Paper (WASP): Coda, but our revels now are not ended. 61
31133350 2019
40
Phrase-final lengthening modulates listeners' perception of vowel duration as a cue to coda stop voicing. 61
31255099 2019
41
Accumulation of glycine betaine in transplastomic potato plants expressing choline oxidase confers improved drought tolerance. 61
30900084 2019
42
Efficient editing DNA regions with high sequence identity in actinomycetal genomes by a CRISPR-Cas9 system. 61
30891508 2019
43
Expert Consensus on Growth and Development Curricula for Predoctoral and Advanced Education Orthodontic Programs. 61
30858279 2019
44
Genesis and mechanisms controlling tornillo seismo-volcanic events in volcanic areas. 61
31089180 2019
45
A cross-linguistic examination of toddlers' interpretation of vowel duration. 61
31576195 2019
46
Thermal modulation of nonlinear ultrasonic wave for concrete damage evaluation. 61
31153317 2019
47
Bubbly flow velocity measurement in multiple scattering regime. 61
30897385 2019
48
CODA-ML: context-specific biological knowledge representation for systemic physiology analysis. 61
31138123 2019
49
Progressive optic nerve changes in cavitary optic disc anomaly: integration of copy number alteration and cis-expression quantitative trait loci to assess disease etiology. 61
31029096 2019
50
Click Nucleic Acid Mediated Loading of Prodrug Activating Enzymes in PEG-PLGA Nanoparticles for Combination Chemotherapy. 61
30884222 2019

Variations for Cavitary Optic Disc Anomalies

ClinVar genetic disease variations for Cavitary Optic Disc Anomalies:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MMP19 GRCh38/hg38 12q13.2(chr12:55845043-55851177)x4copy number gain Pathogenic 180748 12:56238827-56244961 12:55845043-55851177
2 MMP19 GRCh38/hg38 12q13.2(chr12:55845043-55851177)copy number gain Pathogenic 208981 12:56238827-56244961 12:55845043-55851177

Expression for Cavitary Optic Disc Anomalies

Search GEO for disease gene expression data for Cavitary Optic Disc Anomalies.

Pathways for Cavitary Optic Disc Anomalies

GO Terms for Cavitary Optic Disc Anomalies

Sources for Cavitary Optic Disc Anomalies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....